HK1013820A1 - Crystalline form of dihydro-2,3-benzodiazepine derivative. - Google Patents

Crystalline form of dihydro-2,3-benzodiazepine derivative.

Info

Publication number
HK1013820A1
HK1013820A1 HK98115183A HK98115183A HK1013820A1 HK 1013820 A1 HK1013820 A1 HK 1013820A1 HK 98115183 A HK98115183 A HK 98115183A HK 98115183 A HK98115183 A HK 98115183A HK 1013820 A1 HK1013820 A1 HK 1013820A1
Authority
HK
Hong Kong
Prior art keywords
dihydro
crystalline form
benzodiazepine derivative
acetyl
methyl
Prior art date
Application number
HK98115183A
Other languages
English (en)
Inventor
Benjamin Alan Anderson
Marvin Martin Hansen
Jeffrey Thomas Vicenzi
David Lee Varie
Milton Joseph Zmijewski
Edward Grant Groleau
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/412,242 external-priority patent/US6329364B1/en
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of HK1013820A1 publication Critical patent/HK1013820A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HK98115183A 1994-08-31 1998-12-23 Crystalline form of dihydro-2,3-benzodiazepine derivative. HK1013820A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29864594A 1994-08-31 1994-08-31
US08/412,242 US6329364B1 (en) 1994-08-31 1995-03-28 Crystalline form of dihydro-2,3-benzodiazepine derivative

Publications (1)

Publication Number Publication Date
HK1013820A1 true HK1013820A1 (en) 1999-09-10

Family

ID=26970796

Family Applications (1)

Application Number Title Priority Date Filing Date
HK98115183A HK1013820A1 (en) 1994-08-31 1998-12-23 Crystalline form of dihydro-2,3-benzodiazepine derivative.

Country Status (20)

Country Link
EP (1) EP0699678B1 (xx)
JP (1) JP3449835B2 (xx)
CN (1) CN1073996C (xx)
AT (1) ATE262531T1 (xx)
AU (1) AU695424B2 (xx)
BR (1) BR9503843A (xx)
CA (1) CA2157248C (xx)
CZ (1) CZ288679B6 (xx)
DE (1) DE69532739T2 (xx)
DK (1) DK0699678T3 (xx)
ES (1) ES2214491T3 (xx)
FI (1) FI112489B (xx)
HK (1) HK1013820A1 (xx)
HU (1) HU223843B1 (xx)
IL (1) IL115102A (xx)
NO (1) NO309192B1 (xx)
NZ (1) NZ272898A (xx)
PL (1) PL181086B1 (xx)
PT (1) PT699678E (xx)
TR (1) TR199501070A2 (xx)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6017903A (en) 1996-09-27 2000-01-25 Guilford Pharmaceuticals Inc. Pharmaceutical compositions and methods of treating a glutamate abnormality and effecting a neuronal activity in an animal using NAALADase inhibitors
US5824662A (en) 1996-09-27 1998-10-20 Guilford Pharmaceuticals Inc. Treatment of global and focal ischemia using naaladase inhibitors
CZ60499A3 (cs) 1996-09-27 1999-08-11 Guilford Pharmaceuticals Inc. Prostředky s účinkem na NAALADázy, způsoby léčení glutamátové abnormality a způsoby ovlivňování neuronální aktivity u živočichů
UA67749C2 (uk) 1997-08-12 2004-07-15 Егіш Дьйодьсердьяр Рт. Похідна 8-заміщеного-9н-1,3-діоксол/4,5-h//2,3/бензодіазепіну з властивостями амра/каїнатного антагоніста, спосіб одержання похідних, фармацевтична композиція (варіанти), спосіб її одержання та спосіб лікування
SK1792000A3 (en) * 1997-08-12 2000-09-12 Egyt Gyogyszervegyeszeti Gyar 1,3-DIOXOLO(4,5-H)(2,3)BENZODIAZEPINE DERIVATIVES, PROCESS FORì (54) THE PREPARATION THEREOF, PHARMACEUTICAL COMPOSITION CO

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU219778B (hu) 1990-12-21 2001-07-30 Gyógyszerkutató Intézet Közös Vállalat Eljárás N-acil-2,3-benzodiazepin-származékok, savaddíciós sóik és az ezeket tartalmazó gyógyászati készítmények előállítására, valamint a vegyületek egy csoportja, és az ezeket tartalmazó gyógyászati készítmények
HU219777B (hu) * 1993-07-02 2001-07-30 Gyógyszerkutató Intézet Kft. Optikailag aktív 1-(4-nitro-fenil)-4-metil-7,8-metiléndioxi-3,4-dihidro-5H-2,3-benzodiazepin és eljárás előállítására

Also Published As

Publication number Publication date
DE69532739T2 (de) 2005-03-17
DK0699678T3 (da) 2004-06-28
FI112489B (fi) 2003-12-15
FI954066A (fi) 1996-03-01
IL115102A0 (en) 1995-12-08
JP3449835B2 (ja) 2003-09-22
AU3035795A (en) 1996-03-14
ATE262531T1 (de) 2004-04-15
TR199501070A2 (tr) 1996-06-21
CA2157248A1 (en) 1996-03-01
NO953394D0 (no) 1995-08-30
CZ288679B6 (cs) 2001-08-15
DE69532739D1 (de) 2004-04-29
JPH0881469A (ja) 1996-03-26
PL310228A1 (en) 1996-03-04
FI954066A0 (fi) 1995-08-30
CN1073996C (zh) 2001-10-31
HU223843B1 (hu) 2005-02-28
HUT72675A (en) 1996-05-28
PT699678E (pt) 2004-07-30
EP0699678B1 (en) 2004-03-24
NO309192B1 (no) 2000-12-27
CN1128264A (zh) 1996-08-07
IL115102A (en) 1998-12-27
BR9503843A (pt) 1996-09-10
CA2157248C (en) 2000-02-22
AU695424B2 (en) 1998-08-13
PL181086B1 (pl) 2001-05-31
EP0699678A1 (en) 1996-03-06
ES2214491T3 (es) 2004-09-16
NO953394L (no) 1996-03-01
HU9502549D0 (en) 1995-10-30
CZ222195A3 (en) 1996-03-13
NZ272898A (en) 1996-12-20

Similar Documents

Publication Publication Date Title
AU5571190A (en) Retroviral protease inhibiting compounds
FI924381A (fi) Derivat av pyrimidinnukleosid med tumoermotverkande effekt, framstaellning och anvaendning av dessa
EP0422596A3 (en) Tricyclic carbapenem compounds
EP0241901A3 (en) Cephalosporin derivatives, processes for their preparation and antibacterial agents
IL115102A0 (en) Crystalline form of dihydro-2,3-benzodiazepine derivative
IL115101A0 (en) Physical form of dihydro-2,3-benzodiazepine derivative
MY118394A (en) Crystalline form of dihydro-2, 3-benzodiazepine derivative
ES2023760A6 (es) Procedimiento para la preparacion de derivados benzotiazinicos.
DE69221006D1 (de) Mitomycinderivate
MY116368A (en) Physical form of dihydro-2, 3-benzodiazepine derivative
ATE100449T1 (de) 1,3-dioxolan-benzoesaeure und derivate davon.
AU2001225466A1 (en) Pyrimidine derivatives having antitumor effect
AR242030A1 (es) Procedimiento para la preparacion de la forma 2 cristalina del hidrocloruro de ranitidina.

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20110830